Gain of function mutations in p53

Nature Genetics

Volumn 4, Issue 1, 1993, Pages 42-46

  Dittmer, Dirk ^a   Pati, Sibani ^a   Zambetti, Gerard ^a   Chu, Shelley ^a   Teresky, Angelika K ^a   Moore, Mary ^a   Finlay, Cathy ^a   Levine, Arnold J ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELE; ANIMAL CELL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; ENHANCER REGION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PROMOTER REGION; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

ANIMAL; CARRIER PROTEINS; CELL DIVISION; CELL LINE; CLONE CELLS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENES, P53; HUMAN; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; PHENOTYPE; PROTEIN P53; SPECIES SPECIFICITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0027210981     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0593-42     Document Type: Article

References (42)

1. Johnson, P. & Benchimol, S. Friend virus induced murine erythroleukaemia: The p53 locus, in Cancer Surveys 12, (ed. A.J. Levine) 137-151 (Cold Spring Harbor Press, New York, 1992).
2. Baker, S.J. et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 244, 217-221 (1989).
3. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K.U. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53.Science 249, 912-915 (1990).
4. Finlay, C.A., Hinds, P.W. & Levine, A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083-1093 (1989).
5. Chen, P.-L., Chen, Y., Bookstein, R. & Lee, W.-H. Genetic mechanisms of tumour suppression by the human p53 gene. Science 250, 1576-1579 (1990).
6. Farmer, G.E. et al. Wild-type p53 activates transcription in vitro. Nature358, 83-86 (1992).
7. Kern, S. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-32 (1992).
8. Zambetti, G.P., Bargonetti, J., Walker, K., Prives, C. & Levine, A.J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6, 1143-1152 (1992).
9. Bargonetti, J., Friedman, P.N., Kern, S.E., Vogelstein, B. & Prives, C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65, 1083-1091 (1991).
10. El-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W. & Vogelstein, B. Definition of a consensus binding site for p53. Nature Genet. 1, 45-49 (1992).
11. Funk, W.D. et al. A transcriptionally active DNA-binding site for human p53 protein complexes. Molec. cell. Biol. 12, 2866-2871 (1992).
12. Kern, S.E. et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708-1711 (1991).
13. Barnonetti, J. et al. Site-specific binding of wild-type p53 to cellular DMA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6, 1886-1898 (1992).
14. Levine, A.J., Momand, J. & Finlay, C.A. The p53 tumour suppressor gene.Nature 351, 453-456 (1991).
15. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 253, 49-53 (1991).
16. Kern, S.E. et al. Mutant p53 proteins bind DNA abnormally in vitro.Oncogene 6, 131-136 (1991).
17. Mietz, J.A., Unger, T., Huibregtse, J.M. & Howley, P.M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11, 5013-5020 (1992).
18. Yew, P.R. & Berk, A.J. Inhibition of p53 transactivat ion required for transformation by adenovirus E1B 55 Kd protein. Nature 357, 82-85 (1992).
19. Momand, J., Zambetti, G.P., Olson, D.C., George, D. & Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69, 1237-1245 (1992).
20. Zambetti, G.P., Olson, D., Labow, M. & Levine, A.J. A mutant p53 protein is required for the maintenance of the transformed cell phenotype in p53 plus ras transformed cells. Proc. natn. Acad. Sci. U.S.A. 89, 3952-3956 (1992).
21. Martinez, J., Georgoff, I., Martinez, J. & Levine, A.J. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev. 5, 151-159 (1991).
22. Eliyahu, D., Raz, A., Gruss, P., Givol, D. & Oren, M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.Nature 312, 646-649 (1984).
23. Parada, L.F., Land, H., Weinberg, R.A., Wolf, D. & Rotter, V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312, 649-651 (1984).
24. Jenkins, J.R., Rudge, K. & Currie, G.A. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53.Nature 312, 651-654 (1984).
25. Wolf, D., Admon, S., Oren, M. & Rotter, V. Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. Molec. cell. Biol. 4, 552-558 (1984).
26. Shaulsky, G., Goldfinger, N. & Rotter, V. Alterations in tumour development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res. 51, 5232-5237 (1991).
27. Harvey, D. & Levine, A.J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/C murine embryo fibroblasts. Genes Dev. 5, 2375-2385 (1991).
28. Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. & Cline, M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. natn. Acad. Sci. U.S.A. 84, 7716-7719 (1987).
29. Hinds, P.W. et al. Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells: A comparison of the "hot spot" mutant phenotypes. Cell Growth Diff. 1, 571-580 (1990).
30. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K.U. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53.Science 249, 912-915 (1990).
31. Diller, L. et al. p53 functions as a cell cycle control protein in osteosarcomas. Molec. cell. Biol. 10, 5772-5781 (1990).
32. Johnson, P., Gray, D., Mowat, M. & Benchimol, S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumour cells. Molec. cell. Biol. 11, 1-11 (1991).
33. Mercer, W.E. et al. Negative growth regulation in a glioblastoma tumour cell line that conditionally expresses human wild-type p53. Proc. natn. Acad. Sci. U.S.A. 87, 6166-6170 (1990).
34. Eliyahu, D., Michalovitz, D. & Oren, M. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316, 158-160 (1985).
35. Chin, K.V., Ueda, K., Pastan, I. & Gottesman, M.M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science, 255, 459-462 (1992).
36. Werness, B.A., Levine, A.J. & Howley, P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76-79 (1990).
37. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J. & Howley, P.M. The E6 oncoprotein encoded by human papillomavirus 16 or 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
38. Riou, G. et al. Association between poor prognosis in early stage invasive cervical carcinomas and nondetection of HPV DNA. Lancet 335, 1171-1174 (1990).
39. Tan, T.-H., Wallis, J. & Levine, A.J. Identification of the p53 protein domain involved in formation of the simian virus 40 large T antigen-p53 protein complex. J. Virol. 59, 574-583 (1986).
40. Reich, N.C. & Levine, A.J. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 308, 199-201 (1984).
41. Thor, A.D. et al. Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancer. J. natn. Cancer Inst. 84, 845-855 (1992).
42. Martin, H.M., Filipe, M.I., Morris, R.W., Lane, D.P. & Silvestre, F. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer 50, 859-862 (1992).